Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US45256X1037
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG007T9DYW9
IBRX
Immunitybio Inc
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Immunitybio Inc
ISIN
US45256X1037
TICKER
IBRX
MIC
XNAS
REUTERS
IBRX.OQ
BLOOMBERG
IBRX US
Sat, 18.04.2026       ImmunityBio
US45256X1037

NEW ORLEANS, April 17, 2026 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 26, 2026 to file lead plaintiff applications in a securities class action lawsuit against ImmunityBio, Inc. (NasdaqGS: IBRX) ("ImmunityBio" or the "Company"), if they purchased or otherwise acquired the Compan...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Sat, 18.04.2026       ImmunityBio
US45256X1037

NEW YORK, April 17, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (t...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Fri, 17.04.2026       ImmunityBio
US45256X1037

SAN FRANCISCO, April 17, 2026 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026....
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Thu, 16.04.2026       ImmunityBio
US45256X1037

NEW YORK, April 16, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Thu, 16.04.2026       ImmunityBio
US45256X1037

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in ImmunityBio between January 19, 2026 and March 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi p...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Thu, 16.04.2026       ImmunityBio
US45256X1037

SAN DIEGO, April 16, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), have until Tuesday, May 26, 2026 to seek appointment as lead pla...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Thu, 16.04.2026       ImmunityBio
US45256X1037

The Red Flags: What Insiders Allegedly Knew Before Shareholders DidNEW YORK, April 16, 2026 /PRNewswire/ -- SueWallSt announces that a securities class action has been filed against ImmunityBio, Inc. (NASDAQ: IBRX). YOU MAY BE AFFECTE...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Wed, 15.04.2026       ImmunityBio
US45256X1037

Did you buy IBRX securities between January 19, 2026, and March 24, 2026?Affected IBRX Investor SummaryWho: ImmunityBio, Inc. (NASDAQ: IBRX)What: Securities fraud class action lawsuit filedClass Period: January 19, 2026 through March 24, 2026Deadline to Seek Lead Plaintiff Status: May 26, 2026Key Lawsuit Allegations: Material misstatements and/or...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Wed, 15.04.2026       ImmunityBio
US45256X1037

SAN FRANCISCO, April 15, 2026 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026....
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Wed, 15.04.2026       ImmunityBio
US45256X1037

New York, New York--(Newsfile Corp. - April 15, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), of the important May 26, 2026 lead plaintiff deadline in the securities clas...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Wed, 15.04.2026       ImmunityBio
US45256X1037

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in ImmunityBio between January 19, 2026 and March 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi pa...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Wed, 15.04.2026       ImmunityBio
US45256X1037

Philadelphia, Pennsylvania--(Newsfile Corp. - April 15, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) ("ImmunityBio" or the "Company") on behalf of investors who purchased or acquired ImmunityBio shares during the period from January 19, 2026 through March 24, 2026...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Wed, 15.04.2026       ImmunityBio
US45256X1037

Deadline Alert: Understanding Lead Plaintiff Selection Under the PSLRANEW YORK, April 15, 2026 /PRNewswire/ -- IMPORTANT DATE: May 26, 2026. Investors who wish to seek appointment as lead plaintiff in the ImmunityBio, Inc. (NASDAQ: IBRX) securities class action must file a motion by this date....
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 14.04.2026       ImmunityBio
US45256X1037

LOS ANGELES, April 14, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX)....
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 14.04.2026       ImmunityBio
US45256X1037

New York, New York--(Newsfile Corp. - April 14, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), of the important May 26, 2026 lead plaintiff deadline in the securities clas...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 14.04.2026       ImmunityBio
US45256X1037

PHILADELPHIA, April 14, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) ("ImmunityBio" or the "Company") on behalf of investors who purchased or acquired ImmunityBio shares during the period from January 19, 2026 through March 24, 2026 (the "Class Perio...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 14.04.2026       ImmunityBio
US45256X1037

Bernstein Liebhard LLP:Do you, or did you, own shares of ImmunityBio, Inc. (NASDAQ: IBRX)?Did you purchase your shares between January 19, 2026 and March 24, 2026, inclusive?Did you lose money in your investment in ImmunityBio, Inc.?Do you want to discuss your rights?New York, New York--(Newsfile Corp. - April 14, 2026) - Bernstein Liebhard LLP, a...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 14.04.2026       ImmunityBio
US45256X1037

SAN FRANCISCO, April 13, 2026 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026....
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Mon, 13.04.2026       ImmunityBio
US45256X1037

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in ImmunityBio between January 19, 2026 and March 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi pa...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Sun, 12.04.2026       ImmunityBio
US45256X1037

New York, New York--(Newsfile Corp. - April 12, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), of the important May 26, 2026 lead plaintiff deadline in the securities class act...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Sun, 12.04.2026       ImmunityBio
US45256X1037

NEW YORK, April 11, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (t...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Sat, 11.04.2026       ImmunityBio
US45256X1037

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in ImmunityBio between January 19, 2026 and March 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi pa...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Sat, 11.04.2026       ImmunityBio
US45256X1037

Who is Involved: ImmunityBio, Inc. (NasdaqGS: IBRX) investors that purchased between January 19, 2026 and March 24, 2025When to Act: Deadline to file Lead Plaintiff applications is May 26, 2026Basis: ImmunityBio shares fell on FDA warning letter over cancer therapy claims in advertisementNEW YORK and NEW ORLEANS, April 10, 2026 /PRNewswire/ -- Kah...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Fri, 10.04.2026       ImmunityBio
US45256X1037

BENSALEM, Pa., April 10, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN IMMUNITYBIO, INC. (IBRX), CONTA...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Fri, 10.04.2026       ImmunityBio
US45256X1037

Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities between January 19, 2026 and March 24, 2026, inclusive (the “Class Period”), have until Tuesday, May 26, 2026 to seek appointment as lead plaintiff of the ImmunityBio class action lawsuit. Captioned Douglas v....
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Fri, 10.04.2026       ImmunityBio
US45256X1037

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in ImmunityBio between January 19, 2026 and March 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi p...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Fri, 10.04.2026       ImmunityBio
US45256X1037

Philadelphia, Pennsylvania--(Newsfile Corp. - April 10, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) ("ImmunityBio" or the "Company") on behalf of investors who purchased or acquired ImmunityBio shares during the period from January 19, 2026 through March 24, 2026...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.04.2026       ImmunityBio
US45256X1037

SAN FRANCISCO, April 9, 2026 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026....
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.04.2026       ImmunityBio
US45256X1037

Did you buy IBRX securities between January 19, 2026, and March 24, 2026?Affected IBRX Investor SummaryWho: ImmunityBio, Inc. (NASDAQ: IBRX)What: Securities fraud class action lawsuit filedClass Period: January 19, 2026 through March 24, 2026Deadline to Seek Lead Plaintiff Status: May 26, 2026Key Lawsuit Allegations: Material misstatements and/or...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.04.2026       ImmunityBio
US45256X1037

New York, New York--(Newsfile Corp. - April 9, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), of the important May 26, 2026 lead plaintiff deadline in the securities class...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.04.2026       ImmunityBio
US45256X1037

NEW YORK, April 9, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail a...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.04.2026       ImmunityBio
US45256X1037

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage biotechnology company, announced today preliminary select operational results for the fiscal quarter ending March 31, 2026. ImmunityBio reported preliminary net product revenue of approximately $44.2 million during the three-month period ending March 31, 2026, with net product revenue growth in...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.04.2026       ImmunityBio
US45256X1037

If you have suffered a loss on your ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ:IBRX) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Wed, 08.04.2026       ImmunityBio
US45256X1037

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in ImmunityBio between January 19, 2026 and March 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi pa...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Wed, 08.04.2026       ImmunityBio
US45256X1037

LOS ANGELES, April 8, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX) have opportunity to lead the securities fraud class action lawsuit....
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Wed, 08.04.2026       ImmunityBio
US45256X1037

SAN DIEGO, April 8, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities between January 19, 2026 and March 24, 2026, all dates inclusive (the "Class Period"), have until May 26, 2026 to seek appointment as lead plaintiff of the ImmunityBio c...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.04.2026       ImmunityBio
US45256X1037

Institutional investors holding positions in ImmunityBio, Inc. (NASDAQ: IBRX) during the period January 19, 2026 through March 24, 2026 may wish to evaluate lead plaintiff opportunities in a pending securities class action. Shares lost $1.98 per share, a 21% decline, after an FDA Warning Letter exposed allegedly false promotional claims about the C...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.04.2026       ImmunityBio
US45256X1037

SAN FRANCISCO, April 7, 2026 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026....
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.04.2026       ImmunityBio
US45256X1037

New York, New York--(Newsfile Corp. - April 7, 2026) - Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.Should You Join The ImmunityBio Cl...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.04.2026       ImmunityBio
US45256X1037

NEW YORK, April 7, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ImmunityBio, Inc. (NASDAQ: IBRX). Shareholders who purchased shares of IBRX during the class period listed are encouraged to con...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.04.2026       ImmunityBio
US45256X1037

NEW YORK, April 7, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (th...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.04.2026       ImmunityBio
US45256X1037

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in ImmunityBio between January 19, 2026 and March 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi pa...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.04.2026       ImmunityBio
US45256X1037

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced it has submitted a comprehensive response to the U.S. Food and Drug Administration (FDA) Office of Prescription Drug Promotion (OPDP) regarding issues raised on March 13, 2026 related to a television advertisement and a podcast. The company addressed the co...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.04.2026       ImmunityBio
US45256X1037

LOS ANGELES, April 6, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against ImmunityBio, Inc. ("ImmunityBio" or "the Company") (NASDAQ: IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Sharehold...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.04.2026       ImmunityBio
US45256X1037

LOS ANGELES, April 6, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. ("ImmunityBio" or "the Company") (NASDAQ: IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Sun, 05.04.2026       ImmunityBio
US45256X1037

New York, New York--(Newsfile Corp. - April 5, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), of the important May 26, 2026 lead plaintiff deadline in the securities class acti...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Sat, 04.04.2026       ImmunityBio
US45256X1037

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in ImmunityBio between January 19, 2026 and March 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi p...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Sat, 04.04.2026       ImmunityBio
US45256X1037

SAN DIEGO, April 3, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities between January 19, 2026 and March 24, 2026, inclusive (the "Class Period"), have until May 26, 2026 to seek appointment as lead plaintiff of the Immunit...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Sat, 04.04.2026       ImmunityBio
US45256X1037

SAN FRANCISCO, April 3, 2026 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026....
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink
Sat, 04.04.2026       ImmunityBio
US45256X1037

NEW ORLEANS, April 3, 2026 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 26, 2026 to file lead plaintiff applications in a securities class action lawsuit against ImmunityBio, Inc. (NasdaqGS: IBRX) ("ImmunityBio" or the "Company"), if they purchased or otherwise acquired the Company...
Read more
ImmunityBio
Technical Analysis Termsheets Terminal
Permalink